DEFR14A: Kairos Pharma Seeks Stockholder Approval for Equity Line of Credit Agreement at Upcoming Annual Meeting

Kairos Pharma is seeking stockholder approval for several key proposals at its upcoming annual meeting, including the election of directors, ratification of auditors, and approval of an equity line of credit agreement.

Summary

• Kairos Pharma is holding its 2025 Annual Meeting of Stockholders on June 10, 2025, virtually.
• Stockholders of record as of April 29, 2025, are entitled to vote.
• The meeting includes proposals for the election of four directors, ratification of Weinberg & Company, P.A. as the independent auditor, advisory votes on executive compensation and the frequency of such votes, and approval for the issuance of more than 20% of the company's common stock at a price below the minimum price in compliance with NYSE American LLC Company Guide Section 713.
• The company is seeking approval to issue shares under an equity line of credit agreement (ELOC Agreement) with Helena Global Investment Opportunities I Ltd., which allows the company to sell up to $15 million of common stock at a 5% discount to market under certain conditions.
• The board recommends voting FOR all director nominees, FOR the ratification of the auditor, FOR the advisory vote on executive compensation, EVERY YEAR for the frequency of advisory votes on executive compensation, and FOR the issuance of shares under the ELOC Agreement.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol KAPA.
• As of the record date, there were 16,693,306 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing factual information about the upcoming annual meeting and proposals. The potential dilution from the ELOC agreement is a concern, but the funding could be beneficial for the company's research and development.

Positives

• The equity line of credit agreement provides Kairos Pharma with a flexible funding mechanism.
• The virtual annual meeting format expands access for stockholders.
• The board recommends voting FOR all proposals, indicating confidence in the company's direction.
• The company has established standing committees with independent directors for audit, compensation, and nominating and corporate governance.

Negatives

• The potential issuance of a significant number of shares under the ELOC Agreement could dilute existing stockholders' equity.
• The company is seeking approval to issue shares at a discount to market price.
• The company has had some late filings of Section 16(a) reports by officers and directors.

Risks

• The market price of the common stock could decline due to the potential resale of a significant quantity of shares.
• The company may face challenges in selling equity or equity-related securities in the future if a substantial number of shares are sold under the ELOC Agreement.
• The company's reliance on the ELOC Agreement for funding may be affected by market conditions and other factors.
• The issuance of shares of common stock of the Company in connection with the ELOC Agreement could have an anti-takeover effect.

Future Outlook

The company believes that approval of Proposal No. 5 will provide more flexibility in raising funds through the sale of equity, better positioning it to support ongoing clinical trials for ENV105 and pre-clinical trials for KROS101.

Industry Context

Many small biotech companies utilize equity lines of credit as a means of securing funding for research and development activities. The terms of the ELOC agreement, including the discount to market price, are fairly standard for these types of arrangements.

Comparison to Industry Standards

• The use of an equity line of credit (ELOC) is a common financing strategy for small-cap biotech companies like Kairos Pharma, especially those in the clinical trial stage.
• Comparable companies, such as those listed on the Nasdaq Capital Market with similar market capitalizations and R&D needs, often employ ELOCs to access capital quickly.
• The 5% discount to market under the ELOC Agreement is within the typical range for such arrangements, which can vary from 3% to 10% depending on the company's financial health and market conditions.
• The $30 million commitment amount is significant for a company of Kairos Pharma's size and could provide substantial runway for its clinical programs, assuming the company can access the full amount.

Related Party Transactions

• In August 2024, the Company borrowed $0.04 million from one of its officers.
• In April and May 2024, the Company borrowed $0.1 million from three of its officers.
• The officers holding notes payable have since agreed to convert the outstanding loans and principal into shares of common stock of the company, converting at the IPO per share purchase price, following completion of the IPO.

Stakeholder Impact

• Approval of the ELOC Agreement could provide the company with additional funding to advance its clinical trials, potentially benefiting patients.
• Existing stockholders may experience dilution if the company issues a significant number of shares under the ELOC Agreement.
• Employees may benefit from the company's ability to fund its operations and research and development activities.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on June 10, 2025.
• The company will file a Current Report on Form 8-K with the SEC to announce the voting results within four business days after the Annual Meeting.

Key Dates

Keywords

Kairos Pharma, Annual Meeting, Proxy Statement, Equity Line of Credit, ELOC Agreement, Stock Issuance, Director Election, Auditor Ratification, Executive Compensation, Stockholders